Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.
Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Svoboda J. Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort. Journal Of Clinical Oncology 2023, 41: 7542-7542. DOI: 10.1200/jco.2023.41.16_suppl.7542.Peer-Reviewed Original ResearchProgression-free survivalClassic Hodgkin lymphomaECHELON-1 trialBrentuximab vedotinPeripheral neuropathyNon-trial settingOverall survivalLast followInferior progression-free survivalCox proportional hazards modelExperienced grade 1Grade peripheral neuropathyMulti-institution cohortEffect of discontinuationKaplan-Meier methodAdvanced-stage patientsMultivariable logistic regressionProportional hazards modelHigher initial doseDose holdsCommon toxicitiesMedian followDiscontinuation ratesPerformance statusMedian age